---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063955"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:10:45.789003+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit

## Summary
- Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.
- Cash $1.2B including $500M financing; runway into 2028.
- First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.
- BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.
- BEAM-302 fourth cohort dosing started; further data expected H2 2025.

## SEC filing metadata
- accession: 0000950170-25-063955
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/0000950170-25-063955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/beam-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063955
- JSON: https://secwatch.observer/filing/0000950170-25-063955.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.